CD28+ CD8+ Tem细胞通过STAT1依赖的糖皮质激素受体缺陷参与激素难治性急性GVHD
该研究回顾性整合多组学分析异基因造血干细胞移植受者激素治疗前外周血,发现SR-aGVHD中活化CD28+ CD8+效应记忆T细胞扩增,其绝对计数可预测激素抵抗,并揭示STAT1-GR调控轴及JAK抑制的逆转作用。
要点
- 中性粒细胞植入时CD28+ CD8+ Tem细胞绝对计数可预测后续激素抵抗。
- 炎性细胞因子通过STAT1磷酸化抑制GR表达,导致内在激素抵抗。
- JAK抑制在体外逆转细胞因子诱导的激素抵抗,芦可替尼响应伴STAT1活化降低和GR恢复。
核心结论
- SR-aGVHD以CD28+ CD8+ Tem细胞扩增和STAT1依赖的GR缺陷为核心免疫失调,与激素难治机制相关。
研究设计与样本
- 回顾性分析异基因造血干细胞移植受者激素治疗前外周血,采用整合多组学方法,并在独立多中心队列中验证。
主要发现
- SR-aGVHD中活化CD28+ CD8+ Tem细胞扩增,其在中性粒细胞植入时的绝对计数可预测后续激素抵抗,性能与既有临床分类器相当。
- 该表型伴随富含IL-2、IL-27和干扰素的促炎环境。
- 单细胞RNA测序和功能实验提示STAT1-GR调控轴:炎性细胞因子诱导STAT1磷酸化并抑制GR表达。
- JAK抑制在体外挽救细胞因子诱导的激素抵抗;SR-aGVHD患者对芦可替尼的临床响应伴随STAT1活化降低、GR表达恢复和CD8+ Tem细胞池收缩。
临床怎么用
- CD28+ CD8+ Tem细胞计数或可作为SR-aGVHD的生物标志物,辅助识别激素抵抗风险并指导抢先性通路靶向治疗策略。
局限性
- 研究为回顾性设计,样本量及P值等未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-refractory (SR) disease develops in a substantial fraction of patients with grade II to IV acute graft-versus-host disease (aGVHD) and is associated with poor long-term survival. Improved mechanistic insight is needed to identify reliable predictors of steroid resistance. We retrospectively profiled peripheral blood collected before glucocorticoid treatment from allogeneic hematopoietic cell transplantation recipients without aGVHD, with steroid-sensitive aGVHD, and with SR-aGVHD using an integrated multiomics approach, and validated our findings in an independent multicenter cohort. Mass cytometry revealed an expansion of activated CD28+ CD8+ effector-memory T (Tem) cells in SR-aGVHD. Absolute counts of these cells at neutrophil engraftment predicted subsequent steroid resistance in the multicenter cohort and performed comparably to established clinical classifiers. This phenotype was associated with a proinflammatory milieu enriched in interleukin-2 (IL-2), IL-27, and interferon gamma. Single-cell RNA sequencing and functional assays implicated a STAT1-glucocorticoid receptor (GR) regulatory axis, in which inflammatory cytokines induce STAT1 phosphorylation and suppress GR expression, consistent with intrinsic glucocorticoid resistance. JAK inhibition rescued cytokine-induced steroid resistance in vitro, whereas in patients with SR-aGVHD, clinical response to ruxolitinib was accompanied by reduced STAT1 activation, restoration of GR expression, and contraction of the expanded CD8+ Tem cell pool. These findings identify immune dysregulation in SR-aGVHD centered on CD8+ Tem cells with a STAT1-dependent GR deficit and support a mechanistic link to steroid refractoriness. CD28+ CD8+ Tem cell counts may serve as a biomarker of SR-aGVHD and inform the development of preemptive, pathway-targeted therapeutic strategies.
引用
- Pan Z, Deng Y, Huang J, et al. CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD. Blood. 2026. PMID: 41980031. doi:10.1182/blood.2025032587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。